drugset / Trial / NCT00347165

Intravitreal Bevacizumab for Age-Related Macular Degeneration

NCT00347165 ↗

Phase 2 Terminated 50 enrolled Asociación para Evitar la Ceguera en México
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration

Timeline

Start
2005-09
Primary completion
2006-06
Completion
2006-09

Outcome

Outcome not reported

Stopped: “undefined”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 2.5 mg Intravitreal